- Home
- BCDA vs FGI Comparison
BCDA vs FGI Comparison
Compare BCDA & FGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- FGI
- Stock Information
- Founded
- BCDA N/A
- FGI 1987
- Country
- BCDA United States
- FGI United States
- Employees
- BCDA N/A
- FGI N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- FGI Industrial Specialties
- Sector
- BCDA Health Care
- FGI Industrials
- Exchange
- BCDA Nasdaq
- FGI Nasdaq
- Market Cap
- BCDA 11.0M
- FGI 5.5M
- IPO Year
- BCDA N/A
- FGI 2022
- Fundamental
- Price
- BCDA $2.12
- FGI $0.72
- Analyst Decision
- BCDA Strong Buy
- FGI
- Analyst Count
- BCDA 1
- FGI 0
- Target Price
- BCDA $25.00
- FGI N/A
- AVG Volume (30 Days)
- BCDA 195.2K
- FGI 143.0K
- Earning Date
- BCDA 08-12-2025
- FGI 08-06-2025
- Dividend Yield
- BCDA N/A
- FGI N/A
- EPS Growth
- BCDA N/A
- FGI N/A
- EPS
- BCDA N/A
- FGI N/A
- Revenue
- BCDA $3,000.00
- FGI $134,277,102.00
- Revenue This Year
- BCDA N/A
- FGI $7.72
- Revenue Next Year
- BCDA N/A
- FGI $6.94
- P/E Ratio
- BCDA N/A
- FGI N/A
- Revenue Growth
- BCDA N/A
- FGI 11.13
- 52 Week Low
- BCDA $1.63
- FGI $0.46
- 52 Week High
- BCDA $4.66
- FGI $1.20
- Technical
- Relative Strength Index (RSI)
- BCDA 44.60
- FGI 54.58
- Support Level
- BCDA $1.98
- FGI $0.64
- Resistance Level
- BCDA $2.45
- FGI $0.67
- Average True Range (ATR)
- BCDA 0.16
- FGI 0.07
- MACD
- BCDA -0.01
- FGI 0.00
- Stochastic Oscillator
- BCDA 18.00
- FGI 43.59
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.